The challenge of drug resistance in cancer treatment: a current overview
M Nikolaou, A Pavlopoulou, AG Georgakilas… - Clinical & Experimental …, 2018 - Springer
It is generally accepted that recent advances in anticancer agents have contributed
significantly to the improvement of both the disease-free survival and quality of life in cancer …
significantly to the improvement of both the disease-free survival and quality of life in cancer …
Overview of resistance to systemic therapy in patients with breast cancer
AM Gonzalez-Angulo, F Morales-Vasquez… - Breast cancer …, 2007 - Springer
Breast cancer is the most common cancer and the second leading cause of cancer death in
American women. It was the second most common cancer in the world in 2002, with more …
American women. It was the second most common cancer in the world in 2002, with more …
Molecular pathways: regulation and therapeutic implications of multidrug resistance
Multidrug transporters constitute major mechanisms of MDR in human cancers. The ABCB1
(MDR1) gene encodes a well-characterized transmembrane transporter, termed P …
(MDR1) gene encodes a well-characterized transmembrane transporter, termed P …
EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.
K Tanaka, T Iwakuma, K Harimaya… - The Journal of …, 1997 - Am Soc Clin Investig
The translocation t (11; 22) is a common chromosomal abnormality detected both in Ewing's
sarcoma and in primitive neuroectodermal tumor cells. The translocation results in an EWS …
sarcoma and in primitive neuroectodermal tumor cells. The translocation results in an EWS …
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins
PURPOSE: Several studies have reported clinical behavior and chemotherapy resistance in
leiomyosarcomas, but these studies did not differentiate between soft tissue …
leiomyosarcomas, but these studies did not differentiate between soft tissue …
The P-glycoprotein multidrug transporter
O Fardel, V Lecureur, A Guillouzo - General Pharmacology: The Vascular …, 1996 - Elsevier
1. P-glycoprotein (P-gp) is a transmembrane protein involved in ATP-dependent efflux of
various structurally unrelated anticancer drugs. Its overexpression in cancer cells decreases …
various structurally unrelated anticancer drugs. Its overexpression in cancer cells decreases …
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance
MJ Newman, JC Rodarte, KD Benbatoul, SJ Romano… - Cancer research, 2000 - AACR
OC144-093 is a novel substituted diarylimidazole (M r 495) generated using the
OntoBLOCK system, a solid-phase combinatorial chemistry technology, in combination with …
OntoBLOCK system, a solid-phase combinatorial chemistry technology, in combination with …
Clinical trials of P-glycoprotein reversal in solid tumours
P-GLYCOPROTEIN IS a 1280 amino acid surface ATPase which can transport a wide range
of cytotoxic drugs out of tumour cells, including, doxorubicin, vincristine, vinblastine …
of cytotoxic drugs out of tumour cells, including, doxorubicin, vincristine, vinblastine …
Personalized medicine in breast cancer: pharmacogenomics approaches
Breast cancer is the fifth cause of cancer death among women worldwide and represents a
global health concern due to the lack of effective therapeutic regimens that could be applied …
global health concern due to the lack of effective therapeutic regimens that could be applied …
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors.
MA Izquierdo, GL Scheffer, MJ Flens… - The American journal …, 1996 - ncbi.nlm.nih.gov
Multidrug resistance (MDR) to anticancer drugs is a major cause of treatment failure in
cancer. The lung resistance protein LRP is a newly described protein related to MDR in …
cancer. The lung resistance protein LRP is a newly described protein related to MDR in …